Osborne Partners Capital Management LLC Sells 1,622 Shares of Danaher Co. (NYSE:DHR)

Osborne Partners Capital Management LLC cut its position in shares of Danaher Co. (NYSE:DHR) by 1.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 91,931 shares of the conglomerate’s stock after selling 1,622 shares during the quarter. Danaher makes up about 1.4% of Osborne Partners Capital Management LLC’s investment portfolio, making the stock its 14th largest position. Osborne Partners Capital Management LLC’s holdings in Danaher were worth $25,559,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Good Life Advisors LLC bought a new stake in Danaher in the third quarter worth $217,000. Oak Thistle LLC purchased a new position in shares of Danaher in the second quarter worth about $363,000. Norden Group LLC bought a new stake in shares of Danaher in the 1st quarter valued at about $4,151,000. Duality Advisers LP purchased a new stake in Danaher during the 1st quarter valued at about $5,573,000. Finally, Diversified Trust Co grew its position in Danaher by 75.4% during the 2nd quarter. Diversified Trust Co now owns 4,360 shares of the conglomerate’s stock worth $1,090,000 after acquiring an additional 1,874 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Danaher

In other news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 30,059 shares of company stock worth $8,400,897. 11.10% of the stock is owned by insiders.

Danaher Price Performance

DHR opened at $245.39 on Friday. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70. The company has a market cap of $181.76 billion, a price-to-earnings ratio of 41.59, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The stock has a fifty day simple moving average of $269.52 and a two-hundred day simple moving average of $260.35.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the company posted $2.02 EPS. Danaher’s revenue was up 3.1% on a year-over-year basis. Research analysts predict that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Wall Street Analyst Weigh In

DHR has been the subject of several recent research reports. Leerink Partners boosted their price objective on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. TD Cowen upped their price target on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday. Stephens reissued an “overweight” rating and issued a $315.00 price target on shares of Danaher in a report on Wednesday. Stifel Nicolaus boosted their price objective on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research report on Wednesday. Finally, Royal Bank of Canada dropped their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday. Seven investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $287.28.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.